Definium Therapeutics says DT120 met Phase 3 GAD endpoint

Definium Therapeutics said its DT120 fast-dissolving LSD formulation met the Phase 3 Panorama primary endpoint in GAD with rapid effects and mostly mild adverse events, received FDA Breakthrough Therapy status, and is pushing an NDA toward H1 2027.